{"entity":{"id":"nct05957367","kind":"trial","name":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","aka":[],"tldr":"A phase 1/2 trial of Ripretinib in advanced solid tumours, run by Deciphera Pharmaceuticals, LLC, now recruiting.","summary":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies is a phase 1/2 interventional study registered as NCT05957367 by Deciphera Pharmaceuticals, LLC, with 94 participants planned, started 2023-09-28 and due to reach its primary completion in 2027-03. Interventions recorded: Inlexisertib and Ripretinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05957367","url":"https://clinicaltrials.gov/study/NCT05957367"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ripretinib"],"companies":["deciphera"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05957367","phase":"1/2","setting":"A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies","sponsor":"Deciphera Pharmaceuticals, LLC","enrolled":94,"outcomes":[]},"route":"/trials/nct05957367/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"inlexisertib","kind":"drug","name":"Inlexisertib","route":"/drugs/inlexisertib/"},{"id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/"}],"company":[{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/"}]}}